MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.
The study evaluates the benefits of meningococcal conjugate vaccine (MCV4) vaccination against the burden of vaccine-associated Guillain-Barré Syndrome (GBS) using simulation. An 11-year-old cohort was followed over an 8-year period in a simulation model Table 3 Figs. 1 and 2 to estimate health outcomes to assist decision makers in setting policy. Applying a 3% discount rate, MCV4 vaccination would save 2397 quality-adjusted life years (QALYs) while vaccine-attributable GBS could result in 5 QALYs lost. Based on the result, MCV4 vaccination is strongly favored despite possible vaccine-associated GBS risk.
Cho
Bo-Hyun
BH
McKing Consulting Corporation, 1600 Clifton Rd. NE MS E-52, Atlanta, GA 30333, USA. bcho@cdc.gov
Clark
Thomas A
TA
Messonnier
Nancy E
NE
Ortega-Sanchez
Ismael R
IR
Weintraub
Eric
E
Messonnier
Mark L
ML
D000293:Adolescent; D002648:Child; D015331:Cohort Studies; D003661:Decision Support Techniques; D005260:Female; D020275:Guillain-Barre Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000009:adverse effects* / Q000276:immunology*; D016896:Treatment Outcome; D018074:Vaccines, Conjugate / Q000009:adverse effects / Q000276:immunology
D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate